Alyeska Investment Group L.P. grew its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 223.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,271,534 shares of the medical instruments supplier’s stock after purchasing an additional 1,569,746 shares during the period. DENTSPLY SIRONA makes up about 1.1% of Alyeska Investment Group L.P.’s holdings, making the stock its 12th largest holding. Alyeska Investment Group L.P. owned about 0.99% of DENTSPLY SIRONA worth $135,860,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Commonwealth Bank of Australia lifted its stake in DENTSPLY SIRONA by 19.0% during the second quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares in the last quarter. Acrospire Investment Management LLC acquired a new position in DENTSPLY SIRONA during the second quarter worth $113,000. Dupont Capital Management Corp acquired a new stake in shares of DENTSPLY SIRONA in the second quarter valued at $116,000. Massey Quick Simon & CO. LLC acquired a new stake in shares of DENTSPLY SIRONA in the third quarter valued at $124,000. Finally, Korea Investment CORP raised its stake in shares of DENTSPLY SIRONA by 139.9% in the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after acquiring an additional 1,251 shares in the last quarter. Institutional investors own 96.58% of the company’s stock.
Several analysts have recently issued reports on the company. HC Wainwright cut DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price objective on the stock. in a research note on Thursday, November 30th. Stephens assumed coverage on DENTSPLY SIRONA in a research note on Tuesday, November 28th. They issued an “overweight” rating and a $75.00 price objective on the stock. BidaskClub cut DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 2nd. Deutsche Bank assumed coverage on DENTSPLY SIRONA in a research note on Friday, December 8th. They issued a “buy” rating and a $81.00 price objective on the stock. Finally, J P Morgan Chase & Co upgraded DENTSPLY SIRONA from a “neutral” rating to an “overweight” rating and set a $75.00 price objective on the stock in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. DENTSPLY SIRONA currently has an average rating of “Buy” and an average price target of $69.31.
In other news, CFO Nicholas W. Alexos acquired 50,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were bought at an average price of $65.85 per share, with a total value of $3,292,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.90, for a total value of $586,510.00. The disclosure for this sale can be found here. Company insiders own 1.99% of the company’s stock.
DENTSPLY SIRONA Inc. (NASDAQ XRAY) opened at $66.48 on Friday. The company has a market capitalization of $15,269.33, a price-to-earnings ratio of 26.49, a P/E/G ratio of 2.63 and a beta of 1.31. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA Inc. has a twelve month low of $52.53 and a twelve month high of $68.98.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, beating the consensus estimate of $0.66 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. DENTSPLY SIRONA’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.66 earnings per share. equities analysts expect that DENTSPLY SIRONA Inc. will post 2.65 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 12th. Investors of record on Friday, December 29th will be issued a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend is Thursday, December 28th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -10.09%.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://ledgergazette.com/2017/12/17/alyeska-investment-group-l-p-acquires-1569746-shares-of-dentsply-sirona-inc-xray.html.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.